Juno Financial Group LLC Takes Position in Eli Lilly and Company $LLY

Key Points

• Juno Financial Group bought a new stake of 3,926 shares in Eli Lilly valued at about $4.22 million, representing roughly 1.7% of Juno's portfolio and its 14th largest holding.
• Eli Lilly beat Q4 estimates with EPS of $7.54 (vs. $7.48 est.) and revenue of $19.29 billion (vs. $17.85 billion), reported 42.6% year‑over‑year revenue growth, and set FY2026 guidance of $33.50–$35.00 EPS (analysts expect ~33.9).
• Near‑term sentiment is mixed as the Foundayo obesity pill has shown a softer early ramp and GLP‑1 prescription trackers are uneven, but analysts remain largely bullish with an average target near $1,225.

Juno Financial Group LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,926 shares of the company's stock, valued at approximately $4,220,000. Eli Lilly and Company comprises about 1.7% of Juno Financial Group LLC's investment portfolio, making the stock its 14th biggest holding.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $25,000. Miller Global Investments LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $33,000. Dorato Capital Management purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $36,000. Vermillion & White Wealth Management Group LLC raised its stake in Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock worth $27,000 after acquiring an additional 16 shares during the period. Finally, 10Elms LLP raised its stake in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after acquiring an additional 10 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

NYSE LLY opened at $884.88 on Monday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The stock has a market cap of $836.05 billion, a price-to-earnings ratio of 38.56, a PEG ratio of 1.05 and a beta of 0.51. The company's 50 day moving average is $958.83 and its two-hundred day moving average is $985.86. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the firm posted $5.32 EPS. The company's revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 33.9 earnings per share for the current year.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analyst upgrades and higher targets provide support for the shares — firms have recently raised price targets and reiterated bullish views, which underpins medium‑term confidence in execution. Price Target Raised to $1,183.00
• Positive Sentiment: Expanded distribution partnerships broaden commercial reach: Lilly expanded its tie‑up with Hims & Hers to allow prescriptions filled via LillyDirect, increasing patient access to GLP‑1s and Zepbound. This helps commercialization and channel diversification. Eli Lilly (LLY) Expands Partnership with Hims & Hers
• Positive Sentiment: M&A and pipeline progress: recent reports list Lilly acquiring Kelonia (~$7B) and completing a Phase 1 renal study (LY3537982), which reduce early‑stage risk and add potential growth assets. These are constructive for long‑term revenue diversity. Deal Dispatch (mentions Lilly/Kelonia) LY3537982 Renal Study Reaches Completion
• Neutral Sentiment: Upcoming earnings (Q1 report due April 30) is a near‑term catalyst that can amplify moves in either direction — investors are sensitive to any GLP‑1 demand readouts ahead of that release. Weekly GLP-1 prescription data analysis
• Negative Sentiment: Foundayo rollout is tracking below expectations — second‑week U.S. prescriptions were ~3,707, a much smaller early ramp than Novo Nordisk’s oral Wegovy benchmark, raising investor concerns about near‑term obesity market share and pricing/mix. That weaker early uptake is the primary reason shares are under pressure today. Lilly's obesity pill hits nearly 4000 prescriptions
• Negative Sentiment: Weekly GLP‑1 prescription trackers show mixed demand signals (diabetes scripts steady but obesity scripts softer), and heavy insider selling / shifting institutional flows noted in some data sources add to short‑term sentiment risk. Prescription data and insider activity

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Truist Financial restated a "buy" rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Scotiabank restated an "outperform" rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the stock a "buy" rating in a research note on Friday, March 13th. The Goldman Sachs Group set a $1,260.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, Freedom Capital upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average target price of $1,225.33.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.